Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
about
Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesisTreatment of hepatitis C in children: a systematic reviewViral hepatitis and hepatocellular carcinomaHIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: a cross-sectional surveyA new insight into hepatitis C vaccine developmentThe global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysisPEGylation of Interferon-β-1aHepatitis C: a review for primary care physiciansPathogenesis of hepatitis C during pregnancy and childhoodNitazoxanide for chronic hepatitis CPeginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis CExtended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patientsInterferon for interferon nonresponding and relapsing patients with chronic hepatitis CProtease inhibitors in combination with pegylated interferon and ribavirin for adult patients with chronic hepatitis C virusNitazoxanide for chronic hepatitis C virus infectionExtended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks for patients with chronic hepatitis C virus genotype 1 infection having shown slow antiviral responsePegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis CRibavirin plus interferon versus interferon for chronic hepatitis CPegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis CHepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cellsA crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infectionInhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinaseAntiviral therapy of HCV in the cirrhotic and transplant candidate.Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-IIdentification of hepatoprotective flavonolignans from silymarinOutcomes of treatment for hepatitis C virus infection by primary care providersVitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patientsAn update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesAntiviral drugs for viruses other than human immunodeficiency virusIs pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?Genetic history of hepatitis C virus in East AsiaSafety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety TrialClinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States.High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort studyOptimal clinical trial designs for immune-based therapies in persistent viral infectionsRetreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.Variation in hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United KingdomKinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients
P2860
Q21132564-687D00F3-B6C2-43EC-87CC-B8B48125D767Q21136318-4F328D9A-C6DF-4B1F-AED3-66251EBA1E1FQ21245597-AC237724-0922-46CA-8E4E-0198589DC1A7Q21245627-DF90D131-27C1-4C15-B073-CA8570D0E564Q21296858-3FDD4634-6EFA-472A-951B-8582D6CC04F4Q21563395-292A1D1D-B00C-40D2-A94C-B998A0DBFE74Q22241420-148C160E-F8B1-43C9-B87C-C4466B81BD28Q22306040-E1642B9C-FE43-4D7B-B6D5-D310CF73F894Q22809427-12F9F853-55D6-458A-AEF6-E224E6510686Q24197485-5DA6C22D-8218-45BC-A508-FB64D327142EQ24200189-1CA24A1F-658A-42BE-AAC9-60F8CA78239BQ24200534-C63DA181-FA3D-46B0-99F5-4E7CCFD1702DQ24201588-3E8BCBF4-1051-4D7F-B9D7-A7BBE1010FC2Q24202464-5EEDA856-6CEE-4646-A915-9D0616BB423EQ24234215-7B414879-EF36-4095-BC28-F6B781DCA8F4Q24235606-7927B3F9-67C6-4BED-AC9A-371E9A98149EQ24240315-10979E6E-186E-4F9F-875F-9DAF83BB8DC5Q24240879-CBA2C41D-68F0-4B88-93D4-4877636EC28DQ24241360-44CEE4CF-D67E-41A3-BD13-E27A64A3A937Q24297145-51368E80-88D8-4247-9939-96FC2542EBA9Q24301928-38FD8054-ED61-4437-8F1B-19500DA21FA4Q24314907-BA217A01-629D-45C4-A796-BCF3ECB43CC8Q24541565-3BDD9A8E-98DE-47AA-A802-527BFA1B0FABQ24556673-CE89CCA7-8311-4D3F-A168-FEC229759EDAQ24600492-2C6AC235-F024-47DA-B2A2-81DC5A0A7A45Q24601722-634C575B-FBDD-4CD0-83CE-50C2DA3AA056Q24624237-9BC8A304-C440-437A-962D-BF416D464E59Q24632766-CEB9B1EE-74C9-4AD2-A669-61FB62E8F796Q24635330-CD0EBAA5-1D9D-4B49-A68F-959206FE024DQ24644729-634A6532-0316-415D-B555-A6E0BDBC9862Q24655361-1C89C678-B7BD-43B5-B09D-46064134922BQ24683611-6F819350-21B5-43EE-B267-0D63CD33771BQ24791398-D899968F-0C8F-41A0-A530-EFBD2F9823BAQ24799492-FB0DF4D7-5BB6-4EE9-9AFD-8F0574144EA0Q24799820-682CC905-E2EE-4FED-84BF-EBDE7540E631Q24805127-DFD37B76-4463-4464-928C-62B352C8C7C4Q24813993-F3E114F1-A3BF-49C5-9E44-929B3F8031EBQ24815995-FC2D6A2E-AC9C-4036-B8FE-EC2659EB6D75Q25256731-C84DE0B4-53BD-45A0-BD7A-C37ED8685254Q25257004-58AE0150-E0DB-4356-A8A9-185673824327
P2860
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
@ast
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
@en
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
@nl
type
label
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
@ast
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
@en
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
@nl
prefLabel
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
@ast
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
@en
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
@nl
P2093
P50
P3181
P356
P1476
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
@en
P2093
Coleman Smith
Daniel Dhumeaux
Fernando L Gonçales
George Marinos
Joseph Hoffman
Michael W Fried
Mitchell L Shiffman
Moises Diago
P304
P3181
P356
10.1056/NEJMOA020047
P407
P577
2002-09-26T00:00:00Z